An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis

C P Denton; M Engelhart; N Tvede; H Wilson; K Khan; X Shiwen; P E Carreira; F Diaz Gonzalez; C M Black; F H van den Hoogen

doi:10.1136/ard.2008.096123

An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis

C P Denton, M Engelhart, N Tvede, H Wilson, K Khan, X Shiwen, P E Carreira, F Diaz Gonzalez, C M Black, F H van den Hoogen

109 Citations (Scopus)

Abstract

The safety and potential efficacy of a chimaeric anti-tumour necrosis factor alpha monoclonal antibody (infliximab) were examined in diffuse cutaneous systemic sclerosis (dcSSc).

Original language	English
Journal	Annals of the Rheumatic Diseases
Volume	68
Issue number	9
Pages (from-to)	1433-9
Number of pages	7
ISSN	0003-4967
DOIs	https://doi.org/10.1136/ard.2008.096123
Publication status	Published - 2009

Keywords

Adult
Antibodies, Monoclonal
Biological Markers
Biopsy
Cells, Cultured
Collagen Type I
Dermatologic Agents
Female
Fibroblasts
Humans
Male
Middle Aged
Pilot Projects
Scleroderma, Diffuse
Severity of Illness Index
Skin
Treatment Outcome
Tumor Necrosis Factor-alpha

Access to Document

10.1136/ard.2008.096123

Cite this

@article{01835053ca244ea98d1b33ccc1593128,

title = "An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis",

abstract = "The safety and potential efficacy of a chimaeric anti-tumour necrosis factor alpha monoclonal antibody (infliximab) were examined in diffuse cutaneous systemic sclerosis (dcSSc).",

keywords = "Adult, Antibodies, Monoclonal, Biological Markers, Biopsy, Cells, Cultured, Collagen Type I, Dermatologic Agents, Female, Fibroblasts, Humans, Male, Middle Aged, Pilot Projects, Scleroderma, Diffuse, Severity of Illness Index, Skin, Treatment Outcome, Tumor Necrosis Factor-alpha",

author = "Denton, \{C P\} and M Engelhart and N Tvede and H Wilson and K Khan and X Shiwen and Carreira, \{P E\} and \{Diaz Gonzalez\}, F and Black, \{C M\} and \{van den Hoogen\}, \{F H\}",

year = "2009",

doi = "10.1136/ard.2008.096123",

language = "English",

volume = "68",

pages = "1433--9",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier BV",

number = "9",

}

TY - JOUR

T1 - An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis

AU - Denton, C P

AU - Engelhart, M

AU - Tvede, N

AU - Wilson, H

AU - Khan, K

AU - Shiwen, X

AU - Carreira, P E

AU - Diaz Gonzalez, F

AU - Black, C M

AU - van den Hoogen, F H

PY - 2009

Y1 - 2009

N2 - The safety and potential efficacy of a chimaeric anti-tumour necrosis factor alpha monoclonal antibody (infliximab) were examined in diffuse cutaneous systemic sclerosis (dcSSc).

AB - The safety and potential efficacy of a chimaeric anti-tumour necrosis factor alpha monoclonal antibody (infliximab) were examined in diffuse cutaneous systemic sclerosis (dcSSc).

KW - Adult

KW - Antibodies, Monoclonal

KW - Biological Markers

KW - Biopsy

KW - Cells, Cultured

KW - Collagen Type I

KW - Dermatologic Agents

KW - Female

KW - Fibroblasts

KW - Humans

KW - Male

KW - Middle Aged

KW - Pilot Projects

KW - Scleroderma, Diffuse

KW - Severity of Illness Index

KW - Skin

KW - Treatment Outcome

KW - Tumor Necrosis Factor-alpha

UR - https://www.scopus.com/pages/publications/69949138488

U2 - 10.1136/ard.2008.096123

DO - 10.1136/ard.2008.096123

M3 - Journal article

C2 - 18782794

SN - 0003-4967

VL - 68

SP - 1433

EP - 1439

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 9

ER -

An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this